

( )

.

.

.

—

, 72. :

8(812)5533383

8(921)3765742

iluhin-e@yandex.ru



(MTHFR).

**III** –  
, IX, XI, XII.

II,

G20210

V ( ).

4047  
 3,71% 95% ( ) 3,14% 4,33%, —  
 1,89% 1,61% 2,21%. (5,27% V  
 2468 4,42%  
 6,22%), : 2,21%  
 (407 ), 1,23% (650 ), 0,45%  
 (80 ) ( <0,001) (43). 4,8%,  
 18%,  
 7,0 40 – 80 (5, 11, 41).

.V 9,5% 0,7%

(19).  
V ( )

1200 740 7,5%

(15). 1329 V

( ) 4,8% (p<0,0001) (32).

**II** ( ) **G20210**.

4,4% (p<0,0001) (32).

3,4% (52), 2% (40), 0,7% (24).

4,1% 0,2% (19).

**S**, **III**

S- (1.12 %) (1, 33, 44, 51). C (0.13 %– 0.5%), (0.02% – 0.17%),  
4% - 5%.

10% (17, 45). 5% -  
60% - 70% (25,  
56).

(50).

|        | (%)       | (%) | (RR)* |
|--------|-----------|-----|-------|
|        | 0,07-0,16 | 1-3 | 20    |
| PC     | 0,2-0,4   | 3-5 | 10    |
| PS     | 0,03-0,13 | 1,5 | 10    |
| .V ( ) | 3-15      | 20  | 5     |
|        | 1-2       | 4-7 | 2-3   |
|        | 5         | 10  | 2,5   |
| .VIII  | 11        | 25  | 5     |

\* (Relative Risk, RR, risk ratio) –

(3).

( 25 % (50). « - », 70% (38).

20%

(16, 20, 21, 27, 46).

Prandoni

P.

355

1,4 (37).

(8, 30, 55).

V ( )

G20210 ,

V ( )

2 - 4 (4, 31, 36, 42, 46).

Valerio de

Stefano

V ( ),

2,6,

- 3,7,

- 5,4.

(10).

41

V ( ) ( ,  
Paolo Simeoni

(47).

2310

3204

V( )

20! (13).

1,0 - 2,6.

, S,

III -  
(4, 36, 37).

5

III, 6,5

1,7

S (48, 54).

S

10,6 6,7

(44).

(9, 14),

2,5 (12).

2-3 (40).

4 - 20 % (50).

), 4 (9,5 %), 20 (47,6 %). 2 3 (4,8  
 V ( ).  
 13 17 (18).

M. F. 19 (61,3%) ( 31 Hendler  
 S). V ( ),  
 (23). 797 115  
 5 - 6 (34).  
 (7, 53).

(35).

C S, V ( ).

II. V ( )

III, S, V),

( G20210A, ( ) )

( - )

II

(50).

III ( S, V

( )), ELISA- G20210, (26).

( S, )

(39).

Bauer K. (6).

|        |   |     |
|--------|---|-----|
|        |   |     |
|        | * |     |
| , 50 , |   | - V |

|    |  |                            |
|----|--|----------------------------|
|    |  | G20210<br>( - ). ELISA - . |
| 50 |  | , III S                    |

\* ( ) -  
50 .

(50):

1. ;
2. 50 ;
3. , ;
4. 2 ;
5. ;
6. ( , 50 );
7. - ;
8. ;
9. 20 ;
10. ;
11. .  
.  
, , .  
, ( 10 , 10  
24 ).  
6  
.  
(50).

.  
 -  
 , ,  
 ,  
 ,  
 ( )  
 ( ).  
 1,0 – 1,2. ( ),  
 ,  
 , ,  
 , (2).  
 .  
 .  
 ,  
 (28, 29, 42).

Prevention of Recurrent Venous Thromboembolism

(PREVENT)  
 2  
 V  
 ( ) G20210 ( 8,6% 2,2%) (42).  
 ,  
 227  
 23 3 3 10  
 (49).  
 ,  
 2004 (22). 7  
 ,  
 ( ) - 1 (Grade 1).  
 - 2.  
 : -  
 , -  
 , -  
 , , ,  
 5 .

1. 3 ( ' 1 ). .
2. 3 - 6 ( ' 1 + )  
( ' 2 ).
3. , , 6 - 12 ( ' 1 ),  
( ' 2 ).
4. « III, » ( S,  
G20210, VIII).  
( ' ) 12 ( ' 1 + )  
( ' 2 ).  
S, V ( ' ) III,  
6 - 12 , ( ' 1 ).  
( ' 2 ).
5. . .  
. , .  
. . , ,  
. , .

1. Akkawat B, Rojnuckarin P. Protein S deficiency is common in a healthy Thai population. *J Med Assoc Thai*. 2005 Sep;88 Suppl 4:S249-54.
2. Anonymous. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. *BMJ*. 1998;316:894-898
3. Barczyk A, Pierzchala W. Risk factors of venous thromboembolism. *Wiad Lek*. 2001;54 (5-6):311-24.
4. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet*. 2003;362:523-526.
5. Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. *Thromb Haemost* 1997; 77:1219.
6. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. *Ann Intern Med* 2001;135: 367-73.
7. Baarslag HJ, Koopman MM, Hutten BA, Linthorst Homan MW, Buller HR, Reekers JA, van Beek EJ. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. *Eur J Intern Med*. 2004 Dec;15(8):503-507.
8. Crowther, MA, Kelton, JG Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. *Ann Intern Med* 2003;138,128-134.
9. Den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the prevention of secondary deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. *J Thromb Haemost*. 2003;Suppl 1 July 2003:OC161.
10. De Stefano, V, Martinelli, I, Mannucci, PM, et al The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. *N Engl J Med* 1999;341,801-806.
11. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. *Sem Thromb Haemost* 1998; 24:367-79.
12. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost* 1998; 80:874-7.
13. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. *Thromb Haemost*. 2001; 86:809-16.
14. Eichinger S, Stumpf A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. *Thromb Haemost*. 1998;80:566-569.
15. Ehrenforth S, Klinke S, von Depka Prondzinski M, Kreuz W, Ganser A, Scharrer I. Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population. *Dtsch Med Wochenschr*. 1999 Jun 25;124(25-26):783-7.
16. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. *Arch Intern Med*. 2004;164:92-96.

17. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, Mendel M, Kidron M, Bar-On H. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. *J Nutr*. 1999 Sep;129(9):1656-61.
18. Gillet JL, Allaert FA, Perrin M. Superficial thrombophlebitis in non varicose veins of the lower limbs. A prospective analysis in 42 patients. *Cabinet de Medecine Vasculaire, 51 bis Avenue Professeur Tixier, 38300 Bourgoin-Jallieu, France. JJ Mal Vasc*. 2004 Dec;29(5):263-72.
19. Gibson CS, MacLennan AH, Rudzki Z, Hague WM, Haan EA, Sharpe P, Priest K, Chan A, Dekker GA; South Australian Cerebral Palsy Research Group. The prevalence of inherited thrombophilias in a Caucasian Australian population. *Pathology*. 2005 Apr;37(2):160-3.
20. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. *Arch Intern Med*. 2000;160:769-774.
21. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med*. 2000;160:761-768.
22. Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS, MSc, FCCP; Thomas M. Hyers, MD, FCCP; Martin H. Prins, MD and Gary E. Raskob, PhD. Antithrombotic Therapy for Venous Thromboembolic Disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (*Chest*. 2004;126:401S-428S.)
23. Hendler MF, Meschengieser SS, Blanco AN, Alberto MF, Salviu MJ, Gennari L, Lazzari MA. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematologicas Mariano R. Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina. *Am J Hematol*. 2004 Aug;76(4):330-7.
24. Irdem A, Devecioglu C, Batun S, Soker M, Sucakli IA. Prevalence of factor V Leiden and prothrombin G20210A gene mutation. *Saudi Med J*. 2005 Apr;26(4):580-3.
25. Janson JJ, Galarza CR, Murua A, Quintana I, Przygoda PA, Waisman G, Camera L, Kordich L, Morales M, Mayorga LM, Camera MI. Prevalence of hyperhomocysteinemia in an elderly population. *Am J Hypertens*. 2002 May;15(5):394-7.
26. Jack Hirsh and Agnes Y. Y. Lee. How we diagnose and treat deep vein thrombosis. From the Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada. *Blood*, 1 May 2002, Vol. 99, No. 9, pp. 3102-3110.
27. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107:I-22-I-30.
28. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of one month with three months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. *J Thromb Haemost*. 2004;2:743-749.
29. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *N Engl J Med*. 2003;349:631-639.
30. Kyrle, PA, Minar, E, Hirschl, M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. *N Engl J Med* 2000;343:457-462.
31. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. *Thromb Haemost*. 1999;81:684-689.
32. Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E, Di Minno G. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. *Chest*. 2000 Nov;118(5):1405-11.

33. Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. *Int J Hematol*. 2006 Apr;83(3):217-23.
34. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. *Circulation*. 2004 Aug 3;110(5):566-70. Epub 2004 Jul 19.
35. Okrucka A, Pechan J. Evaluation of blood coagulation tests in deep venous thrombosis. *Mater Med Pol*. 1992 Oct-Dec;24(4):256-9.
36. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. *Circulation*. 2003;108:313-318.
37. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med*. 1996;125:1-7.
38. Parsi KA, McGrath MA, Lord RS. Traveller's venous thromboembolism. *Cardiovasc Surg* 2001;9:157-8.
39. Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part II. Treatment and prevention. Emory University School of Medicine, Atlanta, Georgia, USA. *Am Fam Physician*. 2005 Jul 1;72(1):36, 41.
40. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost* 1998; 79: 706-8.
41. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). *Blood* 1995; 85:1504-8.
42. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. *N Engl J Med*. 2003;348:1425-1434.
43. Ridker P.M., Miletich J.P., Hennekens . . ., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. *JAMA* 1997;277(16):1305-7.
44. Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. *Thromb Res*. 2000 Sep 1;99(5):447-52.
45. Shmeleva VM, Kapustin SI, Papayan LP, Sobczynska-Malefora A, Harrington DJ, Savidge GF. Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia. *Thromb Res*. 2003;111(6):351-6.
46. Spiezia L, Bernardi E, Tormene D, et al. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. *Thromb Haemost*. 2003;90:964-966.
47. Simioni, P, Prandoni, P, Lensing, AW, et al The risk of recurrent venous thromboembolism in patients with an Arg506-> Gln mutation in the gene for factor V (factor V Leiden). *N Engl J Med* 1997;336,399-403.
48. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001; 344:1222-31.
49. Schulman, S, Granqvist, S, Holmstrom, M, et al The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: The Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1997;336,393-398.
50. The European Genetics Foundation; The Cardiovascular Disease Educational and Research Trust; The International Union of Angiology; The Mediterranean League on Thromboembolism; Nicolaidis AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, Elkoofy N, Gerotziapas G, Guermazi S, Haas S, Hull R, kalodiki E, Kristof V, Michiels JJ, Myers K, Pineo G, Prandoni P, Romeo G, Samama MM, Simonian S, Xenophonos S Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. *Int Angiol*. 2005 Mar;24(1):1-26.

51. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. *Br J Haematol.* 1994 May;87(1):106-12.
52. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. *Thromb Haemost.* 1999 Nov;82(5):1395-8.
53. Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Corella D, Fontcuberta J, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. *Thromb Haemost.* 2003 Mar;89(3):452-7.
54. Van der Meer FJM, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). *Thromb Haemost* 1997; 78:631-5.
55. Van Den Belt, AG, Sanson, BJ, Simioni, P, et al Recurrence of venous thromboembolism in patients with familial thrombophilia. *Arch Intern Med* 1997;157,2227-2232.
56. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. *Metabolism.* 2001 Dec;50(12):1466-71.
57. N233 09.06.2003 . "
58. « ( ».
- », ., 2006 – 20 .